(Q44407162)

2 December 2017

title

The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys (English)

1 reference

2 December 2017

Cebus apella

1 reference

7

Thomas Werge

1 reference

2 December 2017

Maibritt B Andersen

1

1 reference

2 December 2017

Anders Fink-Jensen

2

1 reference

2 December 2017

Linda Peacock

3

1 reference

2 December 2017

Jes Gerlach

4

1 reference

2 December 2017

Frank Bymaster

5

1 reference

2 December 2017

Jens August Lundbaek

6

1 reference

2 December 2017

language of work or name

English

0 references

publication date

26 March 2003

1 reference

2 December 2017

published in

Neuropsychopharmacology

1 reference

2 December 2017

volume

28

1 reference

2 December 2017

issue

6

1 reference

2 December 2017

page(s)

1168-1175

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300151

2 December 2017

exact match

0 references

cites work

Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Gating and habituation of the startle reflex in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Prestimulus effects on human startle reflex in normals and schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Cholinesterase inhibitors: A new class of psychotropic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Therapeutic opportunities from muscarinic receptor research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Therapeutic opportunities for muscarinic receptors in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Methylphenidate, apomorphine, THIP, and diazepam in monkeys: dopamine-GABA behavior related to psychoses and tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Muscarinic receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Cognition, schizophrenia, and the atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Impaired prepulse inhibition of acoustic startle in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Schizophrenia: more dopamine, more D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Dopamine receptor pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

Pharmacological Specificity of Conditioned Avoidance Response Inhibition in Rats: Inhibition by Neuroleptics and Correlation to Dopamine Receptor Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300151

7 January 2021

Dimensions Publication ID

Identifiers

DOI

10.1038/SJ.NPP.1300151

0 references

1010558127

0 references

1 reference